Different epidemiology of bloodstream infections in COVID-19 compared to non-COVID-19 critically ill patients: a descriptive analysis of the Eurobact II study
Creators: name: Buetti, Niccolò
name: Tabah, Alexis
name: Loiodice, Ambre
name: Ruckly, Stéphane
name: Aslan, Abdullah Tarik
name: Montrucchio, Giorgia
name: Cortegiani, Andrea
name: Saltoglu, Nese
name: Kayaaslan, Bircan
name: Aksoy, Firdevs
name: Murat, Akova
name: Akdoğan, Özlem
name: Saracoglu, Kemal Tolga
name: Erdogan, Cem
name: Leone, Marc
name: Ferrer, Ricard
name: Paiva, José-Artur
name: Hayashi, Yoshiro
name: Ramanan, Mahesh
name: Conway Morris, Andrew
name: Barbier, François
name: Timsit, Jean-François
name: Lipman, Jeffrey
name: Litton, Edward
name: Palermo, Anna Maria
name: Yap, Timothy
name: Eroglu, Ege
name: Hosokawa, Koji
name: Yoshida, Hideki
name: Fujitani, Shigeki
name: Zand, Farid
name: Mahmoodpoor, Ata
name: Tabatabaei, Seyed Mohammad Nasirodin
name: Elrabi, Omar
name: Almekhlafi, Ghaleb A
name: Vidal, Gabriela
name: Aparicio, Marta
name: Alonzo, Irene
name: Namendys-Silva, Silvio A
name: Hermosillo, Mariana
name: Castillo, Roberto Alejandro
name: De Bus, Liesbet
name: De Waele, Jan
name: Hollevoet, Isabelle
name: De Schryver, Nicolas
name: Serck, Nicolas
name: Kovacevic, Pedja
name: Zlojutro, Biljana
name: Ruppe, Etienne
name: Montravers, Philippe
name: Dulac, Thierry
name: Castanera, Jérémy
name: Massri, Alexandre
name: Guesdon, Charlotte
name: Garcon, Pierre
name: Duprey, Matthieu
name: Philippart, François
name: Tran, Marc
name: Bruel, Cédric
name: Kalfon, Pierre
name: Badre, Gaëtan
name: Demeret, Sophie
name: Le Guennec, Loïc
name: Bassetti, Matteo
name: Giacobbe, Daniele
name: Sales, Gabriele
name: Daroui, Ivan
name: Lodi, Giovanni
name: Ippolito, Mariachiara
name: Bellina, Davide
name: Di Guardo, Andrea
name: Rocco, Monica
name: Fiorelli, Silvia
name: Mikstacki, Adam
name: Peichota, Mariusz
name: Pietraszek-Grzywaczewska, Iwona
name: Póvoa, Pedro
name: Krystopchuk, Andriy
name: Teresa, Ana
name: De Figueiredo, António Manuel Pereira
name: Botelho, Isabel
name: Costa, Vasco
name: Cunha, Rui Pedro
name: Gritsan, Alexey
name: Belskiy, Vladislav
name: Furman, Mikhail
name: Martinez, Maria
name: Casares, Vanessa
name: Arnillas, Maria Pilar Gracia
name: Bermudez, Rosana Munoz
name: Ubeda, Alejandro
name: Salgado, Maria
name: Maseda, Emilio
name: De La Rica, Alejandro Suarez
name: Blasco-Navalpotro, Miguel Angel
name: Gallego, Alberto Orejas
name: Prazak, Josef
name: Pagani, JL
name: Abed-Maillard, S
name: Iskit, Arzu Topeli
name: Mehtap, Selcuk
name: Ceyhun, Solakoğlu
name: Kalem, Ayşe Kaya
name: Kurt, Ibrahim
name: Telli, Murat
name: Ozturk, Barcin
name: Baykam, Nurcan
name: Karaali, Ridvan
name: Koksal, Iftihar
name: Bilir, Yeliz
name: Guzeldag, Seda
name: Ersoz, Gulden
name: Evik, Guliz
name: Bayindir, Yasar
name: Ersoy, Yasemin
name: Ercole, Ari
name: Raj, Ashok
name: Zormpa, Artemis
name: Tinaslanidis, George
name: Khade, Reena
name: Roshdy, Ashraf
name: Kannan, Santhana
name: Antrolikar, Supriya
name: Marsden, Nicholas
name: Attwood, Ben
name: Patel, Jamie
name: Gurjar, Mohan
name: Dsilva, Carol
name: Chandran, Jagadish
name: Sanousi, Bashir El
name: Saidahmed, Elfayadh
name: Hamid, Hytham KS
Publisher: name: Apollo - University of Cambridge Repository
Year: 2022
Subjects: Research
NCT03937245
NCT
Bloodstream infection
ICU-acquired
COVID-19
Enterococcus
Bacteremia

description: Funder: European society of Intensive Care Medicine
description: Funder: European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
description: Funder: Norva Dahlia foundation and the Redcliffe Hospital Private Practice Trust Fund
description: Abstract Background The study aimed to describe the epidemiology and outcomes of hospital-acquired bloodstream infections (HABSIs) between COVID-19 and non-COVID-19 critically ill patients. Methods We used data from the Eurobact II study, a prospective observational multicontinental cohort study on HABSI treated in ICU. For the current analysis, we selected centers that included both COVID-19 and non-COVID-19 critically ill patients. We performed descriptive statistics between COVID-19 and non-COVID-19 in terms of patients’ characteristics, source of infection and microorganism distribution. We studied the association between COVID-19 status and mortality using multivariable fragility Cox models. Results A total of 53 centers from 19 countries over the 5 continents were eligible. Overall, 829 patients (median age 65 years [IQR 55; 74]; male, n = 538 [64.9%]) were treated for a HABSI. Included patients comprised 252 (30.4%) COVID-19 and 577 (69.6%) non-COVID-19 patients. The time interval between hospital admission and HABSI was similar between both groups. Respiratory sources (40.1 vs. 26.0%, p &lt; 0.0001) and primary HABSI (25.4% vs. 17.2%, p = 0.006) were more frequent in COVID-19 patients. COVID-19 patients had more often enterococcal (20.5% vs. 9%) and Acinetobacter spp. (18.8% vs. 13.6%) HABSIs. Bacteremic COVID-19 patients had an increased mortality hazard ratio (HR) versus non-COVID-19 patients (HR 1.91, 95% CI 1.49–2.45). Conclusions We showed that the epidemiology of HABSI differed between COVID-19 and non-COVID-19 patients. Enterococcal HABSI predominated in COVID-19 patients. COVID-19 patients with HABSI had elevated risk of mortality. Trial registration ClinicalTrials.org number NCT03937245. Registered 3 May 2019.